RLMD · Relmada Therapeutics Inc
United States · RS rating 54 · As of 2026-11-03
| Price | 4.27 USD |
|---|---|
| 1-day change | +11.2% |
| RS rating (overall / 1M / 3M / 12M) | 54 / 95 / 29 / 93 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 33 / 19 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +50.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +45.7% |
| Market cap (USD) | $760.5M |